129 related articles for article (PubMed ID: 18193218)
1. Differences in radiosensitivity between three HER2 overexpressing cell lines.
Steffen AC; Göstring L; Tolmachev V; Palm S; Stenerlöw B; Carlsson J
Eur J Nucl Med Mol Imaging; 2008 Jun; 35(6):1179-91. PubMed ID: 18193218
[TBL] [Abstract][Full Text] [Related]
2. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.
Ballangrud AM; Yang WH; Palm S; Enmon R; Borchardt PE; Pellegrini VA; McDevitt MR; Scheinberg DA; Sgouros G
Clin Cancer Res; 2004 Jul; 10(13):4489-97. PubMed ID: 15240541
[TBL] [Abstract][Full Text] [Related]
3. The HER2-binding affibody molecule (Z(HER2∶342))₂ increases radiosensitivity in SKBR-3 cells.
Ekerljung L; Lennartsson J; Gedda L
PLoS One; 2012; 7(11):e49579. PubMed ID: 23166716
[TBL] [Abstract][Full Text] [Related]
4. [Effects of interferon-gamma on Her-2/neu expression and antitumor activity of 131I-Herceptin in breast cancer cell lines].
Fan YX; Luo RC; Fang YX; Yan X; Lu CW
Ai Zheng; 2006 Apr; 25(4):443-6. PubMed ID: 16613677
[TBL] [Abstract][Full Text] [Related]
5. HER2-Targeted Multifunctional Silica Nanoparticles Specifically Enhance the Radiosensitivity of HER2-Overexpressing Breast Cancer Cells.
Yamaguchi H; Hayama K; Sasagawa I; Okada Y; Kawase T; Tsubokawa N; Tsuchimochi M
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562708
[TBL] [Abstract][Full Text] [Related]
6. HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo.
Hou J; Zhou Z; Chen X; Zhao R; Yang Z; Wei N; Ni Q; Feng Y; Yu X; Ma J; Guo X
Oncotarget; 2016 Jul; 7(29):45186-45198. PubMed ID: 27286256
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
8. In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction.
Akabani G; Carlin S; Welsh P; Zalutsky MR
Nucl Med Biol; 2006 Apr; 33(3):333-47. PubMed ID: 16631082
[TBL] [Abstract][Full Text] [Related]
9. Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with (99m)Tc-peptide-Z(HER2:342).
Zhang J; Zhao X; Wang S; Wang N; Han J; Jia L; Ren X
Nucl Med Biol; 2015 Jun; 42(6):541-6. PubMed ID: 25735223
[TBL] [Abstract][Full Text] [Related]
10. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
[TBL] [Abstract][Full Text] [Related]
11. Radiation-induced apoptosis and cell cycle alterations in human carcinoma cell lines with different radiosensitivities.
Hunáková L; Chorváth M; Duraj J; Bartosová Z; Sevcíková L; Suliková M; Chovancová J; Sedlák J; Chorváth B; Boljesíková E
Neoplasma; 2000; 47(1):25-31. PubMed ID: 10870683
[TBL] [Abstract][Full Text] [Related]
12. 188Re-HYNIC-trastuzumab enhances the effect of apoptosis induced by trastuzumab in HER2-overexpressing breast cancer cells.
Luo TY; Cheng PC; Chiang PF; Chuang TW; Yeh CH; Lin WJ
Ann Nucl Med; 2015 Jan; 29(1):52-62. PubMed ID: 25238789
[TBL] [Abstract][Full Text] [Related]
13. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
[TBL] [Abstract][Full Text] [Related]
14. Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line.
Ekerljung L; Lindborg M; Gedda L; Frejd FY; Carlsson J; Lennartsson J
Biochem Biophys Res Commun; 2008 Dec; 377(2):489-494. PubMed ID: 18930032
[TBL] [Abstract][Full Text] [Related]
15. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
Chen KT; Lee TW; Lo JM
Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
[TBL] [Abstract][Full Text] [Related]
16. Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice.
Steffen AC; Orlova A; Wikman M; Nilsson FY; Ståhl S; Adams GP; Tolmachev V; Carlsson J
Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):631-8. PubMed ID: 16538504
[TBL] [Abstract][Full Text] [Related]
17. Requirements regarding dose rate and exposure time for killing of tumour cells in beta particle radionuclide therapy.
Carlsson J; Eriksson V; Stenerlöw B; Lundqvist H
Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1185-95. PubMed ID: 16718515
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial MKP1 is a target for therapy-resistant HER2-positive breast cancer cells.
Candas D; Lu CL; Fan M; Chuang FY; Sweeney C; Borowsky AD; Li JJ
Cancer Res; 2014 Dec; 74(24):7498-509. PubMed ID: 25377473
[TBL] [Abstract][Full Text] [Related]
19. 188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment.
Altai M; Wållberg H; Honarvar H; Strand J; Orlova A; Varasteh Z; Sandström M; Löfblom J; Larsson E; Strand SE; Lubberink M; Ståhl S; Tolmachev V
J Nucl Med; 2014 Nov; 55(11):1842-8. PubMed ID: 25278516
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of breast cancer cells overexpressing HER2/neu by 213Bi-Herceptin radioimmunoconjugate.
Zhang DY; Li Y; Rizvi SM; Qu C; Kearsley J; Allen BJ
Cancer Lett; 2005 Feb; 218(2):181-90. PubMed ID: 15670895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
